Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis
Linda van der Tol(Erasmus MC - Sophia Children’s Hospital), Gabor E. Linthorst(Geneeskundige en Gezondheidsdienst), Robin Lachmann(University College London), Derralynn Hughes(Royal Free London NHS Foundation Trust), João Paulo Oliveira(Universidade do Porto), Wim Terryn(Ghent University Hospital), Carla E. M. Hollak(Centre For Development Studies), Einar Svarstad(Haukeland University Hospital), Christoph Wanner(Universitätsklinikum Würzburg), Sandrine Florquin(Amsterdam University Medical Centers), Liffert Vogt(Amsterdam Neuroscience), Camilla Tøndel(Haukeland University Hospital), Michael L. West(Dalhousie University), Alberto Ortíz(Universidad Pontificia de Salamanca), Stephen Waldek, Marieke Biegstraaten(Amsterdam UMC Location University of Amsterdam), Marius A. van den Bergh Weerman(Amsterdam UMC Location University of Amsterdam)
Cited by 64
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|969
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
|Proceedings of the National Academy of Sciences|2008|725